Skip to main content
Figure 1 | Arthritis Research & Therapy

Figure 1

From: Treatment of Muckle-Wells syndrome: analysis of two IL-1-blocking regimens

Figure 1

S100A12 levels in Muckle-Wells syndrome (MWS) patients, comparing interleukin-1 blockade with anakinra (IL-1Ra) and canakinumab (anti-IL-1β). Serum S100A12 levels were measured in MWS patients treated with anakinra (IL-1Ra) at baseline (IL-1Ra bl) and at the short-term end point (IL-1Ra d14) and at last follow-up (IL-1Ra lfup). Similarly levels were determined in patients treated with canakinumab (anti-IL-1β) at baseline (anti-IL-1β bl) and at the short-term end point (anti-IL-1β d8) and at last follow-up (anti-IL-1β lfup). Box plot depicts median, mean (dashed line), 25th and 75th percentiles (box) and 10th and 90th percentiles. S100A12 levels are reduced by anakinra both at short- and long-term end points. Treatment with canakinumab reduced S100A12 levels even further and below the limits of normal (red dashed line).

Back to article page